GovGrant R&D specialists logo – A Source Advisors company

Small Business Equity Tracker – how are the UK’s innovative SMEs faring?

Posted on Tuesday 26 July 2022 by Luke Hamm | Chief Executive Officer

The British Business Bank recently published the latest news from the Small Business Equity Tracker. We take a look at the detail to find out what it tells us about the UK’s innovative SMEs and how they are attracting equity investment.
> Read more

Launch of our latest research into Innovate UK performance

Posted on Thursday 21 July 2022 by Luke Hamm | Chief Executive Officer

We have just released our latest research report, a deep dive analysis into the performance of 18 years of Innovate UK investments, with successful applications for funding totalling over £9.8 billion over this period. ‘Innovate UK: The impact report’ examines funded projects using publicly available data. The data analysed includes 49,527 successful applications relating to 26,242 projects, from 17,698 separate organisations.
> Read more

Day of reckoning for unscrupulous R&D tax providers as HMRC comes calling

Posted on Thursday 4 November 2021 by Luke Hamm | Chief Executive Officer

The latest statistics showing the value of R&D tax relief were published by HMRC in October 2021. And as we noted at the time the total value of R&D tax relief for 2019-2020 is now projected to be nearly £7.5bn – a big number.
> Read more

Rocket into 2021 | Part 3

Posted on Wednesday 3 February 2021 by Somil Goyal | Investment Lead

Over 2020, through the Covid crisis, we at GovGrant helped almost one thousand innovative UK companies, and over hundred investors, achieve value and investment returns from innovation. This led to over £45mn of timely capital flow, helping companies sustain their business in difficult times.
> Read more

All I want for Christmas is vaccines

Posted on Wednesday 2 December 2020 by Adam Simmonds | Investment Research Analyst

The past couple of weeks have been littered with announcement after announcement about vaccines, Pfizer & BioNTech, Moderna, and Oxford University & AstraZeneca. All have been featuring in the news with their promising results that are potentially paving the way for a return to normality.
> Read more